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The equine herpesvirus 1 (EHV-1) homolog of the herpes simplex virus type 1 (HSV-1) tegument phosphoprotein, aTIF
(Vmw65; VP16), was identified previously as the product of open reading frame 12 (ORF12) and shown to transactivate
immediate early (IE) gene promoters. However, a specific virion protein corresponding to the ORF12 product has not been
identified definitively. In the present study the ORF12 protein, designated ETIF, was identified as a 60-kDa virion component
on the basis of protein fingerprint analyses in which the limited proteolysis profiles of the major 60-kDa in vitro transcription/
translation product of an ORF12 expression vector (pT7-12) were compared to those of purified virion proteins of similar
size. ETIF was localized to the viral tegument in Western blot assays of EHV-1 virions and subvirion fractions using polyclonal
antiserum and monoclonal antibodies generated against a glutathione-S-transferase–ETIF fusion protein. Northern and
Western blot analyses of EHV-1-infected cell lysates prepared under various metabolic blocks indicated that ORF12 is
expressed as a late gene, and cross reaction of polyclonal anti-GST-ETIF with a 63.5-kDa HSV-1 protein species suggested
that ETIF and HSV-1 aTIF are antigenically related. Last, DNA band shift assays used to assess ETIF-specific complex
formation indicated that ETIF participates in an infected cell protein complex with the EHV-1 IE promoter TAATGARAT
motif. q 1997 Academic Press
Equine herpesvirus 1 (EHV-1) is an important pathogen have been observed. Both VZV and HSV-1 aTIFs (referred
to throughout as VTIF and HTIF, respectively) have beenof horses and causes a variety of disease states, includ-
identified as structural components of the tegument (8,ing respiratory illness, neurological disorders, and abor-
17); however, mutational analysis revealed that HTIF istion. In addition, as a member of the Alphaherpesvirinae
essential for HSV-1 capsid maturation and virion assem-subfamily of viruses, EHV-1 has proven useful as a model
bly (18, 19), whereas VTIF is dispensable (20). Thesesystem for the various outcomes of herpesviral infec-
observations suggest that the role of VTIF as a viriontions. Like other Alphaherpesviruses studied to date,
component differs significantly from that of its HSV coun-EHV-1 gene expression is regulated in three temporal
terpart. These aTIF proteins also differ in their primaryclasses (1 – 4), and previous studies have shown that
structures and transactivation domains. HTIF requires anEHV-1 particles transactivate expression of the first, im-
acidic carboxy terminus, which has been identified asmediate early (IE or a), gene class (5). This virion-associ-
its transactivation domain, whereas functional VTIF lacksated activity has been ascribed to the product of EHV-
the corresponding final 80 acidic amino acids (15, 16,1 open reading frame 12 (ORF12; 6, 7), which exhibits
21, 22). Sequence analysis of the EHV-1 ORF12 genesignificant sequence homology with the herpes simplex
indicated that, like VZV, the ORF12 gene product (ETIF)virus type 1 (HSV-1) a-transinducing factor (aTIF) gene,
lacks the acidic carboxy terminal transactivation domainUL48, and varicella zoster virus (VZV) ORF10 (8–12).
(12). Furthermore, mutational analysis of ETIF determinedWhile aTIF proteins have been characterized for several
that the C-terminal 7 amino acid residues appear to beother Alphaherpesviruses, including HSV-1 (13), HSV-2
necessary, but not sufficient, for ETIF transactivational(14), VZV (15), and bovine herpesvirus (BHV; 16), a spe-
function (23). In addition, fusion proteins containing thecific virion protein corresponding to the EHV-1 ORF12
HTIF protein binding domain and ETIF C-terminus didproduct has not been identified. Although the known aTIF
not have transinducing activity, suggesting that se-homologs share the ability to transactivate IE gene pro-
quences from other regions of ETIF are required (23).moters, some interesting differences among them also
In HSV-1 infection, IE gene transactivation is mediated
by a multiprotein complex which includes the virion struc-
tural protein HTIF, the ubiquitous cellular transcription1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (706) 721-6276. E-mail: gcaughma@mail.mcg.edu. factor Oct-1 (24–26), and another cellular component
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designated HCF (9, 10, 27). HTIF does not bind directly capsid/tegument-enriched subvirion fractions were pre-
pared by incubation of radiolabeled purified virions in 1%to DNA but rather interacts with Oct-1 protein bound
directly to the consensus TAATGARAT (R purine) motif, Nonidet P-40 and 1% deoxycholate for 1 hr at 377, fol-
lowed by centrifugation at 34,000 g for 30 min and collec-a conserved sequence present in all five HSV-1 IE pro-
moters (28, 29) as well as in the promoter of the single tion of the envelope (supernatant) and nucleocapsid/teg-
ument (pellet) fractions (34, 35). Radiolabeled protein pro-EHV-1 IE gene (5). While HTIF/TAATGARAT complexes
have been demonstrated in DNA band shift studies (30), files from the envelope- and nucleocapsid/tegument-
enriched subvirion fractions, and from mock- and EHV-similar complexes have not been identified with ETIF.
Recent studies by Elliott and O’Hare (31) have found that 1-infected RK cell lysates are included in Fig. 1A for com-
parsion (lanes f–i, respectively).other octamer elements in the EHV-1 IE promoter are
targets for ETIF/Oct-1 complex formation and may play Using the resulting autoradiogram as a guide, the pro-
tein bands corresponding to the in vitro-translated ORF12a role in ETIF-mediated transactivation. Thus, the present
study was undertaken to identify the ETIF protein in viri- protein and a similarly sized doublet from the purified
virion profile (designated V2), as well as bands immedi-ons and to characterize it further by comparing ETIF to
its other a-herpesviral homologs with respect to virion ately above and below that region (V1 and V3), were
excised from the dried polyacrylamide gel and used inlocalization, temporal regulation, antigenic relatedness
to HTIF, and its ability to complex with the EHV-1 IE partial proteolytic digestion assays (Protein Fingerprint-
ing System, Promega). The rehydrated gel slices wereTAATGARAT motif.
An ORF12 expression vector, pT7-12, was constructed loaded onto a 15% SDS–polyacrylamide gel in the pres-
ence of 40 mg/ml endoproteinase lys-C or endoprotei-by insertion of an EcoRI/SphI fragment spanning ORF12
(derived from EHV-1 Kentucky A strain genomic plasmid nase glu-C using conditions described by the manufac-
turer. The resulting proteolytic digest profiles were visu-pRIG; 19) into the polylinker region of the pcDNAI/Amp
vector (Invitrogen, San Diego, CA). The resulting orienta- alized by autoradiography. As shown in Fig. 1B, the
number and sizes of the peptides produced by digestiontion allowed use of either the T7 promoter for in vitro
transcription/translation applications or the human cyto- of the ORF12 protein and the V2 doublet were very simi-
lar. In contrast, the ORF12 and V2 profiles differed signifi-megalovirus (CMV) IE promoter for eukaryotic transient
expression assays. The functional activity of pT7-12 was cantly from those of in vitro-translated luciferase protein
(lane e) and of the other two viral bands (V1 and V3)assessed by cotransfection of RK13 cells with pIEbgal,
which harbors 1.45 kb of the EHV-1 IE gene promoter tested (data not shown). From these results, it appeared
that, although the V2 sample consisted of two MW spe-region (0813 to /637 nucleotides) fused to the Esche-
richia coli lac Z gene according to methods described cies, the predominant V2 protein was structurally related
to the ORF12 product.previously (6). Cells cotransfected with pT7-12 and pIEb-
gal exhibited a 645-fold increase in b-galactosidase ex- Densitometric analysis of the profiles of radiolabeled
proteins from envelope-stripped virions indicated that,pression compared to that of cells transfected with only
the pcDNAI/pIEbgal constructs, indicating that pT7-12 whereas 99% of the major capsid protein partitioned to
the nucleocapsid/tegument-enriched fraction (Fig. 1A,expressed an active IE transactivator.
The pT7-12 plasmid was used for in vitro transcription/ double arrowhead), the putative ETIF doublet was pres-
ent in approximately equal amounts in the nucleocapsid/translation of ORF12 using the TNT lysate system (Pro-
mega, Madison, WI) according to the manufacturer’s pro- tegument- and the envelope-enriched fractions (Fig. 1A,
lanes f and g). The finding that the putative ETIF proteintocol. The resulting major [35S]methionine-labeled protein
product migrated as a single band with an apparent mo- was abundant in the envelope fraction compared to the
relatively low concentration of major capsid protein indi-lecular weight of 60 kDa in SDS–PAGE (Fig. 1A, lane d),
a size slightly larger than the ORF12 product’s predicted cated that this result was not due simply to inefficient
enrichment of the subvirion fractions. In addition, themolecular weight of 53,644 daltons. Using this in vitro-
translated product as a standard for comparison, candi- observation that treatment of viral particles with concen-
trations of trypsin as high as 1 mg/ml in the absence ofdate proteins for the ORF12 in vivo counterpart were
identified and isolated from SDS–PAGE profiles of puri- NP-40 (35) did not abolish the ETIF doublet (data not
shown) indicated that the purified virions were still intactfied EHV-1 (KyA) virion proteins. Radiolabeled extracellu-
lar viral particles were purified from the culture fluids of and that the ETIF protein was not associated with the
outer surface of the envelope. These results are consis-infected BHK cells as described previously (32, 33) and
maintained in medium containing 20 mCi/ml [35S]- tent with those of McLauchlan et al. (36) who, in their
characterization of components of HSV-1 virions and L-methionine. Proteins of pT7-12 TNT lysates and purified
virus were separated by 9% SDS–PAGE (Fig. 1A, lanes particles, found that NP-40 treatment of purified virions
partially solubilized Vmw65 (HTIF). Thus, it appears thatd and e, respectively); the gels were dried and subjected
to autoradiography to visualize the positions of the radio- ETIF is loosely associated with the tegument and, like
HTIF, can be released easily into the envelope fraction.labeled protein bands. In addition, envelope- and nucleo-
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FIG. 1. Identification of ETIF as a virion component. (A) SDS–PAGE of in vitro transcribed/translated ORF12. pT7-12 was used as template in
an in vitro transcription/translation kit (Promega). Resulting [35S]methionine-labeled proteins were separated by SDS–PAGE and visualized by
autoradiography. Lanes a–d depict the protein profiles derived from the addition of no DNA, pcDNAI vector DNA, and luciferase control plasmid
DNA, respectively. Lanes e–g represent the profiles of purified virions, nucleocapsid/tegument-, and envelope-enriched subfractions, respectively.
Viral protein bands excised for further study are indicated as V1, V2, and V3. The arrowhead in lane g indicates the presence of the V2 bands in
the envelope-enriched fraction; the double arrowhead identifies the major capsid protein. Lanes h and i are profiles of mock- and EHV-1-infected
RK cell lysates included for comparison. (B) Partial proteolytic digestion of a 60-kDa virion-associated doublet (V2) and the pT7-12 in vitro transcription/
translation product. Parallel sets of gel slices containing the [35S]methionine-labeled protein bands corresponding to the pT7-12 in vitro translation
product and a doublet of similar size from purified virions were excised from a dried 9% polyacrylamide gel, rehydrated, and loaded into a 3%
stacking gel along with 40 mg/ml of the endoproteinases lys-c and glu-c as indicated. The mixtures were electrophoresed to the stacking/separating
gel interface; the electrophoresis was halted for 30 min and then continued into a 15% separating gel. The resulting peptide fragments were detected
by autoradiography.
The temporal class of ORF12 expression was as- cultures sampled at 18 hr p.i. (37). These results indi-
cated that ORF12 expression is highly dependent uponsessed by Northern blot analyses (Fig. 2A). Total RNA
was prepared from EHV-1-infected RK13 cells cultured DNA replication. A second 1.2-kb late transcript also was
identified. This mRNA species most likely representsunder immediate early, early, and late conditions as de-
scribed in the figure legend. Fifteen micrograms of each ORF11, since the 0.45-kb fragment used as probe over-
laps the 3* end of ORF11 (12).sample was separated by 1.2% agarose/formaldehyde
gel electrophoresis, and Northern analysis was per- To monitor the kinetics of ETIF protein synthesis during
lytic infection and to characterize further its presenceformed by hybridization to a 0.45-kb EcoRI/BglII [32P]-
dCTP-labeled fragment from EHV-1 genomic clone in viral particles, specific antibodies against the ORF12
protein were generated. A GST (glutathione-S-trans-BamHI H. This probe is homologous to the sequence
053 to/399 relative to the ORF12 translational start site. ferase)–ORF12 fusion protein was generated as de-
scribed in Fig. 2B, affinity purified, and used to immunizeAn mRNA species of approximately 1.4 kb corresponding
to ORF12 was detected in abundance in the unblocked rabbits and mice for the production of polyclonal and
monoclonal antibodies (mAbs), respectively, as pre-infected cell cultures (Fig. 2A, lane d), but was detectable
in RNA from PAA-blocked cultures only after prolonged viously described (38, 39). The resulting rabbit antiserum
and mAb-containing hybridoma supernatants wereexposure of the autoradiogram (Fig 2A, lane c). This low-
level expression likely relates to the fact that PAA inhibi- tested for GST–ORF12-specific antibodies in Western
blots as previously described (39).tion of EHV-1 DNA synthesis is not 100%; approximately
4% residual viral DNA synthesis occurred in PAA-blocked The time course of ETIF synthesis in lytically infected
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FIG. 2. Determination of the temporal class of ETIF. (A) Northern analysis of ORF12 expression under immediate early, early, and late conditions.
RNA extracted from RK13 cell cultures infected with 10 PFU EHV-1/cell under immediate early (75 mg/ml cycloheximide, 00.5–3 hr p.i.; 10 mg/ml
actinomycin D, 3–7 hr p.i.; IE; lane b), early (200 mg/ml phosphonoacetic acid, 0–7 hr p.i.; E, lane c), or late (no metabolic inhibitors, harvested at
7 hr p.i.; L; lane d) conditions were separated in a 1.2% agarose/formaldehyde gel, blotted, and hybridized with a 0.45-kb [32P]dCTP-labeled EcoRI/
BglII fragment from genomic clone BamHI H. Lane a contained mock-infected RK13 cell RNA as control. (B) Immunoblot analysis of infected cell
extracts harvested at 2–12 hr p.i. using an ORF12-specific mAb. ORF12-specific antibodies were generated by inserting the SacI fragment of ORF12
(which encodes amino acids 54 –473 of the ETIF protein) into SacI-digested pGEX-KG plasmid. Induction of BL21(DE3)pLysE E. coli harboring the
recombinant plasmid, designated pGEX-KGORF12, resulted in over-production of the 76-kDa fusion product which was then purified by GST-
Sepharose affinity chromatography. Lyophilized GST-ORF12 protein was resuspended in PBS, emulsified, and used to inject mice and rabbits for
the production of ORF12-specific mAbs and polyclonal antiserum, respectively. Mock (M)- and EHV-1-infected RK cell lysates prepared at 2, 4, 6,
8, 10, and 12 hr p.i. (lanes b–g, respectively) were separated by SDS–PAGE in a 9% polyacrylamide gel, blotted, and reacted with ORF12-specific
mAb. The arrowhead indicates the 60 kDa ETIF protein species. (C) Immunoblot analyses of purified virions, subvirion fractions and IE-, E-, and L-
infected cell lysates using GST-ORF12-specific rabbit antiserum. Purified EHV-1 virions (lane a), nucleocapsid/tegument-enriched subfraction (lane
b), envelope-enriched subfraction (lane c), HSV-1 virions (lane d), and mock- (lane e) and EHV-1-infected equine dermis cell lysates infected under
immediate early (lane f), early (lane g), or late (lane h) conditions were separated by SDS–PAGE in a 9% polyacrylamide gel, blotted, and reacted
with GST-ORF12-specific antiserum (1:100) as previously described (31).
RK cells was analyzed by Western blots using anti-ORF12 ion fractions confirmed that the 60-kDa doublet found to
be related structurally to the in vitro-translated ORF12mAbs. As shown in Fig. 2B, ETIF protein was detectable
by 6 hr p.i. and continued to accumulate throughout the product in peptide fingerprint assays also reacted with
the GST–ORF12-specific antiserum (Fig. 2C, lane a). Insampling period. Analysis of purified virions and subvir-
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addition, assay of nucleocapsid/tegument (lane b) and
envelope fractions (lane c) indicated that ETIF was pres-
ent in significant amounts in both fractions. However,
ETIF was not detectable in highly purified nucleocapsid
preparations using anti-ETIF mAbs (data not shown).
These results are consistent with those of the SDS –
PAGE analysis of radiolabeled virion fractions, described
above, and confirm ETIF’s localization within the tegu-
ment of EHV-1 particles.
The marked reduction in detectable ORF12-specific
mRNA in PAA-treated-infected cells indicated that ORF12
is expressed as a late gene. To extend this finding, ly-
sates of RK cells infected with EHV-1 under immediate
early, early, and late conditions were subjected to West-
ern blot analysis using anti-GST–ORF12 polyclonal anti-
serum. As expected, ETIF was not expressed as an im-
mediate early protein (Fig. 2C, lane f; 38, 39). ETIF also
was not detected in lysates of cells infected and main-
tained under early conditions (lane g), while the ETIF
doublet was readily apparent in lysates prepared from
nondrug-treated-infected cells (late conditions; lane h).
These results complement the RNA data and indicate
that the ORF12 product is a late protein.
With respect to the two ETIF protein species, it was
interesting to note that their relative proportions differed
significantly depending on whether the protein was de-
rived from purified virions or infected cell lysates (com- FIG. 3. DNA band shift assay demonstrating ETIF complex formation
pare lanes a and h). The two ETIF species associated at the EHV-1 TAATGAGAT motif. 32P-labeled TAATGAGAT oligonucleo-
with purified virions appeared in approximately equal tide (1 ng) was mixed with 5 mg mock-infected (M, lane a) or EHV-1-
infected (lanes b–g) BHK cell nuclear extracts. DNA/protein complexesamounts, whereas the slower migrating species predom-
were separated on 3.5% nondenaturing polyacrylamide gels in 0.51inated in infected cell lysates. Studies are in progress to
TBE buffer and visualized by autoradiography. Supershift assays were
characterize further the two ETIF species and determine performed by addition of 4 ml of ETIF-specific antiserum (lane c), preim-
the significance of this difference in their distribution. In mune rabbit serum (PRS, lane d), or anti-major DNA binding protein
addition, the GST–ORF12 antiserum also reacted with a mAb hybridoma supernatant (anti-MDBP, lane g) prior to addition of
labeled oligomer. Competition assays were performed by preincubationsingle HSV-1 virion protein species approximately 63.5
of the binding reaction with a 100-fold molar excess of unlabeled E4kDa in size (lane d); the mobility of this cross-reactive
(lane e) or TAATGAGAT (lane f) oligomer. The putative Oct-1 complex
band corresponds closely to that of HTIF. Thus, ETIF and is designated by a small arrowhead; supershifted ETIF-specific com-
HTIF appear to be antigenically related. plex is designated by a large arrowhead.
Finally, GST–ORF12-specific antiserum was used to
identify the ORF12 protein as a component of DNA/pro-
tein complexes in DNA band shift assays. Mock- or EHV- the loss of this complex and the appearance of a new
complex with reduced mobility (lane b). Identification of1-infected BHK cell nuclear extracts were prepared as
previously described (39, 40). An oligonucleotide and its ETIF as a component of this infected cell-specific com-
plex was confirmed by preincubation of the infected cellcomplement corresponding to the sequence 0605 to
0644 of the EHV-1 IE promoter and spanning the TAA- nuclear extract with GST–ORF12-specific antiserum
(lane c). These conditions resulted in the appearance ofTGAGAT motif were annealed and [32P]-end-labeled.
Binding reactions containing nuclear protein and TAA- a unique, low mobility complex, while the addition of
preimmune rabbit serum had no such effect (compareTGAGAT oligonucleotide were carried out for 20 min at
room temperature using incubation conditions previously lanes c and d). These data demonstrate for the first time
that the ORF12 gene product, ETIF, participates in a DNA/described (31). Binding reactions were separated by non-
denaturing polyacrylamide electrophoresis and DNA/ protein complex involving the TAATGAGAT element.
Elliott and O’Hare (31) previously identified four regionsprotein complexes were visualized by autoradiography.
Incubation of the TAATGAGAT-bearing sequence with of the EHV-1 IE gene promoter that harbor Oct-1 binding
sequences (designated E1–E4), and demonstrated Oct-mock-infected BHK nuclear extracts resulted in the for-
mation of a major complex (Fig. 3, lane a), whereas incu- 1, HCF, and ETIF complex formation with each of these
four sequences in DNA band shift assays. Based onbation with EHV-1-infected BHK nuclear extracts induced
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these data, the investigators concluded that ETIF re- address whether ETIF complexes with the TAATGARAT
motif. In the present study, EHV-1-infected cell nuclearquires the same cellular factors for complex formation
as does HTIF, and thus may interact with its target se- extracts demonstrated strong complex formation with the
TAATGARAT element of the EHV-1 IE promoter, despitequence(s) by a similar mechanism. In the present study,
the TAATGAGAT/protein interaction was greatly reduced its lack of a perfect octamer motif. Furthermore, this com-
plex could be specifically supershifted by the addition ofin the presence of an excess of nonlabeled E4 oligomer
(lane e), supporting Elliott and O’Hare’s conclusion that, ETIF-specific antiserum, indicating that ETIF is a contrib-
uting component. Thus, even though it appears that thelike HTIF, ETIF requires Oct-1 for complex formation. Ad-
dition of excess nonlabeled TAATGAGAT oligonucleotide conserved TAATGARAT element may not to be essential
for ETIF function in transient expression and DNA bandwas less efficient than the E4 oligomer, but still capable
of reducing protein binding (compare lanes e and f). This shift assays, it may still serve as a major control element
of the EHV-1 IE promoter in the context of a viral infection.result may reflect the fact that the EHV-1 TAATGARAT
element contains an imperfect Oct-1 consensus se- Experiments are in progress to characterize further the
function of ETIF as a structural component of the EHV-1quence, whereas E4’s Oct-1 site is a perfect match of
the canonical octamer consensus site (ATGCAAAT) and virion, to compare the roles of the cis-acting promoter
elements required for ETIF-specific complex formationtherefore is more efficient at competing for Oct-1. Finally,
the possibility that the viral protein–DNA complexes re- to those of other Alphaherpesviruses, and to determine
whether ORF12 is an essential EHV-1 gene.sulted from nonspecific binding by the EHV-1 major DNA-
binding protein (MDBP) was ruled out by including an
anti-MDBP mAb (39) in the DNA-binding reactions (lane ACKNOWLEDGMENTS
g). Addition of anti-MDBP mAb had no effect on mobility
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has been identified in viral particles, localized to the tegu-
ment and found to be antigenically related to HSV-1 aTIF.
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